You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 18, 2016

Lex Mundi Guide on Health Industry Laws 2016 – Thailand Chapter

Tilleke & Gibbins and Lex Mundi

Published by Tilleke & Gibbins in association with Lex Mundi, the International Guide on Health Industry Laws  provides an overview of healthcare systems in 19 jurisdictions worldwide. The Thailand chapter of the guide, written by industry specialists at Tilleke & Gibbins, covers the following subjects:

  • Healthcare schemes: The Social Security Scheme, Civil Servant Medical Benefit Scheme, and personal payment
  • Authorities and associations: The Ministry of Public Health, Office of Permanent Secretary, and Departments for Medical Services, Development of Thai Traditional and Alternative Medicine, Mental Health, Disease Control, Health, Health Service Support, Medical Sciences, and the Thai Food and Drug Administration (FDA)
  • Health laws: Sanatorium Act, Professional Practice of the Art of Healing Act, Medical Professionals Act, Consumer Case Procedure Act, Drug Act, and Medical Instrument Act
  • Compulsory licensing: The Patent Act, preconditions to seek a compulsory license, requirement to pay royalties to patent owners and hold negotiations, and the compulsory licensing period
  • Surrogacy: The Surrogacy Bill, legal parental rights to children born via surrogacy, jurisdiction of the Juvenile and Family Court, same-sex couples, and commercial surrogacy
  • Clinical trials: Regulatory authorities, obtaining approval from the Ethical Review committee for Research in Human Subjects or research institute or university, authority of the FDA, and the draft bill covering human research
  • Stem cell research: The Medical Council’s Regulation on Medical Ethics Regarding Stem Cell Research for Human Treatment, requirements, and draft regulations
  • Mobile health applications: Use of mobile health applications by health professionals

This publication forms part of a series of Global Practice Guides prepared by Lex Mundi member firms in more than 100 jurisdictions.

RELATED INSIGHTS​ 

June 9, 2021
The latest updates to Practical Law’s Life Sciences Global Guide feature two revised sections from Tilleke & Gibbins attorneys in the firm’s Jakarta office—“Medicinal Product Regulation and Product Liability in Indonesia,” and “Pharmaceutical IP and Competition Law in Indonesia.” “Medicinal Product Regulation and Product Liability in Indonesia” covers a range of regulatory issues related to the marketing and selling of pharmaceutical products, including the following: Regulatory overview, including relevant laws and authorities, scope, definitions, and general procedures for pharmaceuticals, biologicals, and medical devices and health care IT Pricing, government funding, and reimbursement: Structure of Indonesia’s health care system, price regulation, and reimbursement Clinical trials Manufacturing and distribution Marketing: Authorization for marketing medicinal products, parallel imports and cross-border trade in medicines Restrictions on dealings with health care professionals Selling restrictions Advertising and promotion Data privacy Packaging, labeling, and tracking Product safety, quality, and liability Local establishment, representation, and residency requirements Reform The full “Medicinal Product Regulation and Product Liability in Indonesia” section can be accessed on the Practical Law website. “Pharmaceutical IP and Competition Law in Indonesia” first goes over the country’s legal and regulatory environment for patents and trademarks in relation to pharmaceutical business operations in the jurisdiction. The section then turns to competition law issues, with the Q&A format focusing on how the country’s competition laws and regulations affect the pharmaceutical sector. Readers are also given information on how to properly comply with Indonesian competition law, including in the licensing of medicines and pharmaceutical technology. The full “Pharmaceutical Intellectual Property and Competition Law in Indonesia” section can be found on the Practical Law website. Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas.
May 27, 2021
The new regulations for using Indonesia’s SIAPIK system have the potential to affect companies’ advertising plans and help maintain the relevance and effectiveness of Indonesia’s drug advertising regulatory environment
May 27, 2021
On March 1, 2021, the government of Vietnam promulgated Decree No. 14/2021/ND-CP on Penalties for Administrative Violations Involving Animal Husbandry (Decree 14). The new decree took effect on April 20 and, among other contents, repeals the regulations on animal feed found in Decree No. 64/2018/ND-CP dated May 7, 2018. In the field of animal feed, notable penalties of Decree 14 include the following: Penalty forms and levels For each administrative violation, the violator will be imposed a monetary penalty, which is the main penalty form. For the same violation, the monetary penalty level applied to an organization is double the amount applied to an individual. In addition, based on the nature and extent of the violation, additional penalties may be imposed on the violators, including confiscation of violating items, and confiscating Certificates of Eligibility to manufacture animal feeds. Violations of regulations on declaring product information A fine of up to VND 3 million (USD 130) will be imposed for the act of changing information on product labels that has been published on the Portal of the Ministry of Agriculture and Rural Development (MARD) without conducting the notification procedure to inform the MARD of such change. A fine of up to VND 7 million (USD 300) will be imposed for the act of deliberately falsifying or erasing contents of documents or making false declarations in the applications for animal feed products on the Portal of the MARD. Violation of regulations on quality in importing animal feed A fine of up to VND 25 million (USD 1,080) will be imposed for the act of importing each animal feed having (i) a quantitative content of each quality criterion lower than the minimum level or higher than the maximum level compared with the standards announced or written on the goods label; or (ii)